Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03845452
Other study ID # RECHMPL18_0447
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2016
Est. completion date January 31, 2019

Study information

Verified date February 2019
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Aim of this study is to compare the association of muscle mass and functionality with mortality among chronic haemodialysis

- the involvement of malnutrition inflammation and atherogenesis syndrome (increase in C reactive protein and decrease in serum albumin) on voluntary muscle strength impairment and phyiscal activity.

- the relationship between voluntary muscle strength and mortality

- the relationship between voluntary muscle strength and physical activity


Description:

Aim of this study is to compare the association of muscle mass and functionality with mortality among chronic haemodialysis

- the involvement of malnutrition inflammation and atherogenesis syndrome (increase in C reactive protein and decrease in serum albumin) on voluntary muscle strength impairment and phyiscal activity.

- the relationship between voluntary muscle strength and mortality

- the relationship between voluntary muscle strength and physical activity


Recruitment information / eligibility

Status Completed
Enrollment 187
Est. completion date January 31, 2019
Est. primary completion date January 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion criteria:

- chronic kidney disease patient with extrarenal replacement therapy by hemodialysis for at least 3 months

- stable clinical condition (absence of infection, stroke or acute decompensation)

Exclusion criteria:

- chronic kidney disease without extrarenal replacement therapy

- history of renal transplantation

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Uhmontpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality at 2 years Mortality at 2 years 2 years